Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 1.00 |
| ▸ | PPARD | Q03181 | 6/20 | 1.00 |
| ▸ | PPARA | Q07869 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | F7 | P08709 | 5/20 | 1.00 |
| ▸ | F3 | P13726 | 5/20 | 1.00 |
| ▸ | FABP4 | P15090 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | FFAR1 | O14842 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | DUSP3 | P51452 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16685715 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL15880317 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| Linoleic Acid SCHEMBL20856202 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL22498259 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL22498256 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| Arachidic Acid SCHEMBL20528087 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| Linoleic Acid SCHEMBL25294178 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL22498258 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| Dihomo-Gamma-Linolenic Acid SCHEMBL20656585 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 | |
| SCHEMBL21411004 | 1.00 | PPARG (1.00) | PPARGPPARDPPARAALDH1A1F7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 841 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642830-A1 | (METH)ACRYLATED ISOCYANURATE MIXTURE, PROCESS FOR PREPARING SAME, AND USES THEREOF | ARKEMA France (FR) | 2025-11-05 | — | — | EP | claimed |
| US-12370173-B2 | Pet food compositions that modulate vitamin D and bone mineral content in a companion animal | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-07-29 | — | — | US | claimed |
| EP-3554254-B1 | COMPOSITIONS AND METHODS THAT MODULATE BACTERIA IN A COMPANION ANIMAL | NESTLE SA (CH) | 2025-05-07 | — | — | EP | claimed |
| CN-118416041-A | Application of free fatty acid in preparation of medicine for treating myeloproliferative neoplasm | 中南大学湘雅二医院 | 2024-08-02 | — | — | CN | claimed |
| WO-2024141286-A1 | (METH)ACRYLATED ISOCYANURATE MIXTURE, PROCESS FOR PREPARING SAME, AND USES THEREOF | ARKEMA FRANCE (FR) | 2024-07-04 | — | — | WO | claimed |
| US-20240010601-A1 | METHODS TO PRODUCE VERY LONG CHAIN FATTY ACIDS (VLCFA) | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2024-01-11 | — | — | US | claimed |
| EP-3554263-B1 | COMPOSITIONS AND METHODS THAT MODULATE DIGESTIBILITY IN A COMPANION ANIMAL | NESTLE SA (CH) | 2023-07-19 | — | — | EP | claimed |
| EP-3554256-B1 | COMPOSITIONS AND METHODS THAT MODULATE VITAMIN D AND BONE MINERAL CONTENT IN A COMPANION ANIMAL | NESTLE SA (CH) | 2023-07-19 | — | — | EP | claimed |
| US-20230210815-A1 | COMPOSITIONS AND METHODS THAT MODULATE VITAMIN D AND BONE MINERAL CONTENT IN A COMPANION ANIMAL | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-07-06 | — | — | US | claimed |
| EP-4203940-A1 | METHODS TO PRODUCE VERY LONG CHAIN FATTY ACIDS (VLCFA) | The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) | 2023-07-05 | — | — | EP | claimed |
| WO-2004033698-A2 | PROCESS FOR PRODUCING MICROBIAL FAT OR OIL HAVING LOWERED UNSAPONIFIABLE MATTER CONTENT AND SAID FAT OR OIL | SUNTORY LIMITED (JP) | 2004-04-22 | — | — | WO | claimed |
| EP-1390378-A1 | PHARMACEUTICALLY ACTIVE URIDINE ESTERS | Trommsdorff GmbH & Co. KG Arzneimittel (DE) | 2004-02-25 | — | — | EP | claimed |
| US-6677470-B2 | NOVEL COMPOSITIONS OF CONJUGATED LINOLEIC ACIDS; HUMAN AND ANIMAL NUTRITION | NATURAL ASA (NO) | 2004-01-13 | — | — | US | claimed |
| US-20030144353-A1 | Functional acylglycerides | NATURAL ASA (NO) | 2003-07-31 | — | — | US | claimed |
| WO-2003043972-A2 | FUNCTIONAL ACYLGLYCERIDES | NATURAL AS (NO) | 2003-05-30 | — | — | WO | claimed |
| WO-2003035051-A2 | THE USE OF PROTON SEQUESTERING AGENTS IN DRUG FORMULATIONS | INHALE THERAPEUTIC SYSTEMS, INC. (US) | 2003-05-01 | — | — | WO | claimed |
| EP-0965578-B1 | Novel triglyceride and composition comprising the same | SUNTORY LTD (JP) | 2003-04-16 | — | — | EP | claimed |
| WO-2002088159-A1 | PHARMACEUTICALLY ACTIVE URIDINE ESTERS | TROMMSDORFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2002-11-07 | — | — | WO | claimed |
| US-6248909-B1 | STRUCTURE OF THE HUMAN BREAST MILK TYPE, WHICH TRIGLYCERIDE HAS A SATURATED FATTY ACID HAVING 16-18 CARBON ATOMS AT THE POSITION 2, AND UNSATURATED ACYL AT THE POSITION 1 AND/OR 3 | SUNTORY LIMITED (JP) | 2001-06-19 | — | — | US | claimed |
| EP-0965578-A1 | Novel triglyceride and composition comprising the same | SUNTORY LIMITED (JP) | 1999-12-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144353-A1 | Functional acylglycerides | ELOVL3, CPT1B, ELOVL6 | PPARG 67/4885PPARD 251/4885PPARA 120/4885 |
| US-12370173-B2 | Pet food compositions that modulate vitamin D and bone mineral content in a companion animal | CYP24A1, GC, VDR | PPARG 983/4885PPARD 289/4885PPARA 1149/4885 |
| US-20230210815-A1 | COMPOSITIONS AND METHODS THAT MODULATE VITAMIN D AND BONE MINERAL CONTENT IN A COMPANION ANIMAL | CYP24A1, VDR, CYP2R1 | PPARG 617/4885PPARD 189/4885PPARA 646/4885 |
| US-20240010601-A1 | METHODS TO PRODUCE VERY LONG CHAIN FATTY ACIDS (VLCFA) | ELOVL1, ELOVL3, HACD3 | PPARG 200/4885PPARD 256/4885PPARA 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.